Analyst firms · J.P. Morgan · YMAB

J.P. Morgan YMAB price target and rating history

Y-mAbs Therapeutics Inc. (YMAB) · Health Care

J.P. Morgan rates Y-mAbs Therapeutics Inc. (YMAB) Underweight with a $7 price target, as of its latest action on Oct 31, 2022. It has published 3 rating actions on YMAB since November 2021, including 0 upgrades and 2 downgrades.

Current rating
Underweight
Price target
$7
Median target, all firms
Too few
Actions on YMAB
3

J.P. Morgan price target on YMAB

$30$19$720222023202420252026
J.P. Morgan price target on YMAB, each point a stated target, November 2021 to October 2022.

Every J.P. Morgan rating on YMAB

Questions about J.P. Morgan and YMAB

What is J.P. Morgan's price target for YMAB?
J.P. Morgan's latest stated price target for Y-mAbs Therapeutics Inc. (YMAB) is $7, from its action on Oct 31, 2022.
What is J.P. Morgan's rating on YMAB?
J.P. Morgan rates YMAB Underweight, a bearish rating, as of Oct 31, 2022.
When did J.P. Morgan last change its view on YMAB?
On Oct 31, 2022, J.P. Morgan downgrades to Underweight from Neutral, price target $16 to $7.

More YMAB rating histories

All J.P. Morgan ratingsYMAB news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.